BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 24225966)

  • 21. Paraneoplastic pemphigus associated with fatal bronchiolitis obliterans and intractable mucosal erosions: Treatment with cyclosporin in addition to steroid, rituximab and intravenous immunoglobulin.
    Namba C; Tohyama M; Hanakawa Y; Murakami M; Shirakata Y; Matsumoto T; Suemori K; Ishii N; Hashimoto T; Sayama K
    J Dermatol; 2016 Apr; 43(4):419-22. PubMed ID: 26506947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel antibodies in the treatment of non-Hodgkin's lymphoma.
    Bhat SA; Czuczman MS
    Neth J Med; 2009 Sep; 67(8):311-21. PubMed ID: 19767657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
    Salles G; Seymour JF; Offner F; López-Guillermo A; Belada D; Xerri L; Feugier P; Bouabdallah R; Catalano JV; Brice P; Caballero D; Haioun C; Pedersen LM; Delmer A; Simpson D; Leppa S; Soubeyran P; Hagenbeek A; Casasnovas O; Intragumtornchai T; Fermé C; da Silva MG; Sebban C; Lister A; Estell JA; Milone G; Sonet A; Mendila M; Coiffier B; Tilly H
    Lancet; 2011 Jan; 377(9759):42-51. PubMed ID: 21176949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab therapy for autoimmune haematological diseases.
    Barcellini W; Zanella A
    Eur J Intern Med; 2011 Jun; 22(3):220-9. PubMed ID: 21570637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab.
    Borker A; Choudhary N
    Indian Pediatr; 2011 Aug; 48(8):627-32. PubMed ID: 21918268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. B cell depletion in autoimmune disease.
    Gorman C; Leandro M; Isenberg D
    Arthritis Res Ther; 2003; 5 Suppl 4(Suppl 4):S17-21. PubMed ID: 15180893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peri-infusional adverse reactions to rituximab in patients with non-Hodgkin's lymphoma.
    Arredondo-Garza T; Majluf-Cruz A; Vela-Ojeda J; Mariscal-Ramírez I; Solis-Anaya L; Lopez-Gutiérrez JR; Guadarrama CH; Rico-Curiel E; Armenta-San Sebastián JA; Castañeda-Hernández G
    Arch Med Res; 2013 Oct; 44(7):549-54. PubMed ID: 24120421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pneumocystis jiroveci pneumonia in patients with systemic lupus erythematosus after rituximab therapy.
    Tsai MJ; Chou CW; Lin FC; Chang SC
    Lupus; 2012 Jul; 21(8):914-8. PubMed ID: 22287506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mixed-type autoimmune haemolytic anaemia: unusual cases and a case associated with splenic T-cell angioimmunoblastic non-Hodgkin's lymphoma.
    Win N; Tiwari D; Keevil VL; Needs M; Lakhani A
    Hematology; 2007 Apr; 12(2):159-62. PubMed ID: 17454198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myocardial infarction after rituximab treatment for rheumatoid arthritis: Is there a link?
    van Sijl AM; van der Weele W; Nurmohamed MT
    Curr Pharm Des; 2014; 20(4):496-9. PubMed ID: 23565629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficiency therapy with rituximab in patients with non-Hodgkin's lymphomas].
    Kriachok IA; Filonenko KS; Gubareva GO; Tytorenko IB; Novosad OI; Kadnikova TV; Aleksik OM; Martynchyk AV; Kushchevyĭ ÉV; Pastushenko IaV; Kutsenko LB
    Lik Sprava; 2011; (1-2):117-21. PubMed ID: 21954645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab for the treatment of lupus erythematosus panniculitis.
    Moreno-Suárez F; Pulpillo-Ruiz A
    Dermatol Ther; 2013; 26(5):415-8. PubMed ID: 24099073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained clinical response to rituximab in a case of life-threatening overlap subepidermal autoimmune blistering disease.
    Li Y; Foshee JB; Sontheimer RD
    J Am Acad Dermatol; 2011 Apr; 64(4):773-8. PubMed ID: 20494477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose chemotherapy followed by autologous and allogeneic hematopoietic stem cell transplantation in patients with follicular non-Hodgkin’s lymphoma in the rituximab era.
    Escobar IG; Sánchez de Ibarguen BC; de Juan VC; Alonso CM; García MM; Ruíz AC; Pulla MP
    Tumori; 2015; 101(1):2-7. PubMed ID: 25702654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Case report; a case of MALT lymphoma related cryoglobulinemic MPGN responded to combined chemotherapy with rituximab].
    Kurashige M; Yokoo T; Miyazaki Y; Tsuboi N; Hayakawa H; Utsunomiya Y; Hosoya T
    Nihon Naika Gakkai Zasshi; 2011 Apr; 100(4):1054-7. PubMed ID: 21626845
    [No Abstract]   [Full Text] [Related]  

  • 36. Cancer-Associated Retinopathy and Treatment with Intravenous Immunoglobulin Therapy. A Seldom Used Approach?
    Ramos-Ruperto L; Busca-Arenzana C; Boto-de Los Bueis A; Schlincker A; Arnalich-Fernández F; Robles-Marhuenda Á
    Ocul Immunol Inflamm; 2021 Feb; 29(2):399-402. PubMed ID: 31710513
    [No Abstract]   [Full Text] [Related]  

  • 37. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
    Ramos-Casals M; García-Hernández FJ; de Ramón E; Callejas JL; Martínez-Berriotxoa A; Pallarés L; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Pérez-Alvarez R; Micó ML; Medrano F; Gómez de la Torre R; Díaz-Lagares C; Camps M; Ortego N; Sánchez-Román J;
    Clin Exp Rheumatol; 2010; 28(4):468-76. PubMed ID: 20525449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diffuse aggressive lymphoma.
    Fisher RI; Miller TP; O'Connor OA
    Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004).
    Scheinberg M; Hamerschlak N; Kutner JM; Ribeiro AA; Ferreira E; Goldenberg J; Kiss MH; Chahade WH
    Clin Exp Rheumatol; 2006; 24(1):65-9. PubMed ID: 16539821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma.
    Hosing C; Saliba RM; Körbling M; Acholonu S; McMannis J; Anderlini P; Giralt S; De Lima M; Okoroji GJ; Couriel DR; Champlin R; Khouri IF; Donato ML
    Leuk Lymphoma; 2006 Jul; 47(7):1290-4. PubMed ID: 16923559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.